National Library of Medicine (NLM). MeSH Descriptor Data 2021: Hearing Loss. https://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=DetailsSearch&Term=%22Hearing+Loss%22%5BMeSH+Terms%5D (2021).
Luxon, L. M. Hearing Loss. In Encyclopedia of the Neurological Sciences 2nd edn (eds. Aminoff, M. J. & Daroff, R. B.) 533–538 (Academic Press, Oxford, 2014).
World Health Organization. Deafness and hearing loss. Geneva: World Health Organization. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss (2025).
World Health Organization. World report on hearing. Geneva: World Heath Organization. https://www.who.int/publications/i/item/9789240020481 (2021).
GBD 2019 Hearing Loss Collaborators. Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019. Lancet 397, 996–1009 (2021).
Olusanya, B. O. et al. Developmental disabilities among children younger than 5 years in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Glob. Health 6, e1100–e1121 (2018).
Brown, C. S., Emmett, S. D., Robler, S. K. & Tucci, D. L. Global hearing loss prevention. Otolaryngol. Clin. North Am. 51, 575–592 (2018).
Kraaijenga, V. J. C. et al. Cochlear implant performance in children deafened by congenital cytomegalovirus—a systematic review. Clin. Otolaryngol. 43, 1283–1295 (2018).
Hilditch, C. et al. Does screening for congenital cytomegalovirus at birth improve longer term hearing outcomes? Arch. Dis. Child. 103, 988 (2018).
Deltenre, P. & Van Maldergem, L. Chapter 158—Hearing loss and deafness in the pediatric population: causes, diagnosis, and rehabilitation. in Handbook of Clinical Neurology, Vol. 113 (eds Dulac, O., Lassonde, M. & Sarnat, H. B.) 1527–1538 (Elsevier, 2013).
Tarshish, Y., Leschinski, A. & Kenna, M. Pediatric sudden sensorineural hearing loss: diagnosed causes and response to intervention. Int. J. Pediatr. Otorhinolaryngol. 77, 553–559 (2013).
Wilson, B. S., Tucci, D. L., O’Donoghue, G. M., Merson, M. H. & Frankish, H. A Lancet Commission to address the global burden of hearing loss. Lancet 393, 2106–2108 (2019).
Peters, M. D. J. et al. Chapter 11: Scoping reviews (2020 version). in JBI Manual for Evidence Synthesis (eds Aromataris, E. & Munn, Z.) (JBI, 2020).
Tricco, A. C. et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann. Intern. Med. 169, 467–473 (2018).
Johri M. & Wilson, B. S. LCOHL: Vaccination for prevention of worldwide hearing loss. https://doi.org/10.17605/OSF.IO/EGDSM. Vol. 2023 (OSF, 2023).
World Health Organization. Immunization, Vaccines and Biologicals: Vaccine-Preventable Diseases (including pipeline vaccines). https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases (2025).
World Health Organization. Strategic Advisory Group of Experts on Immunization (SAGE): WHO Vaccine Position Papers. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers (2025).
World Health Organization. Table 1: Summary of WHO Position Papers – Recommendations for Routine Immunization. https://www.who.int/publications/m/item/table1-summary-of-who-position-papers-recommendations-for-routine-immunization (2024).
European Centre for Disease Prevention and Control. Vaccination schedules for individual European countries and specific age groups. Available from: https://www.ecdc.europa.eu/en/immunisation-vaccines/EU-vaccination-schedules (2024).
Centers for Disease Control and Prevention. Child and Adolescent Immunization Schedule by Age : Recommendations for Ages 18 Years or Younger. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html#table-1 (2025).
Centers for Disease Control and Prevention. Adult Immunization Schedule by Age Recommendations for Ages 19 Years or Older. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html#table-age (2025).
Government of Canada. Table 1: Routine childhood immunization schedule, infants and children (birth to 17 years of age). https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-13-recommended-immunization-schedules.html#p1c12a2 (2024).
Government of Canada. Vaccination for adults. https://www.canada.ca/en/public-health/services/vaccination-adults.html (2023).
World Health Organization. WHO Vaccine Pipeline Tracker. https://docs.google.com/spreadsheets/d/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM/pubhtml (2025).
Serajuddin, U. & Hamadeh, N. New World Bank country classifications by income level: 2020-2021. in World Bank Blogs (Data Blog, 2020).
Grimshaw, J. A Knowledge Synthesis Chapter. in A Guide to Knowledge Synthesis (Canadian Institutes of Health Research, 2010).
World Health Organization. Product & Delivery Research. https://www.who.int/teams/immunization-vaccines-and-biologicals/product-and-delivery-research (2025).
World Health Organization. Product and delivery research. https://www.who.int/teams/immunization-vaccines-and-biologicals/product-and-delivery-research (2025).
World Health Organization. Handbook on health inequality monitoring: with a special focus on low- and middle-income countries. https://www.who.int/publications/i/item/9789241548632 (2013).
van Heerbeek, N. et al. Effect of combined pneumococcal conjugate and polysaccharide vaccination on recurrent otitis media with effusion. Pediatrics 117, 603 (2006).
Straetemans, M., Palmu, A., Auranen, K., Zielhuis, G. A. & Kilpi, T. The effect of a pneumococcal conjugate vaccine on the risk of otitis media with effusion at 7 and 24 months of age. Int. J. Pediatr. Otorhinolaryngol. 67, 1235–1242 (2003).
Menser, M. A., Hudson, J. R., Alan, M. M. & Laurence, J. U. Epidemiology of congenital rubella and results of rubella vaccination in Australia. Rev. Infect. Dis. 7, S37–S41 (1985).
Le, T.-M., Rovers, M. M., Veenhoven, R. H., Sanders, E. A. M. & Schilder, A. G. M. Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year. Eur. J. Pediatr. 166, 1049–1052 (2007).
Hashimoto, H., Fujioka, M., Kinumaki, H. & Kinki Ambulatory Pediatrics Study Group. An office-based prospective study of deafness in mumps. Pediatr. Infect. Dis. J. 28, 173–175 (2009).
Cheffins, T., Chan, A., Keane, R. J., Haan, E. A. & Hall, R. The impact of rubella immunisation on the incidence of rubella, congenital rubella syndrome and rubella-related terminations of pregnancy in South Australia. BJOG Int. J. Obstet. Gynaecol. 105, 998–1004 (1998).
Darin, N. & Hanner, P. Changes in prevalence, aetiology, age at detection, and associated disabilities in preschool children with hearing impairment born in Göteborg. Dev. Med. Child Neurol. 39, 797–802 (1997).
Dayan, G. H. et al. Recent resurgence of mumps in the United States. N. Engl. J. Med. 358, 1580–1589 (2008).
Gao, Z. et al. Models of strategies for control of rubella and congenital rubella syndrome—a 40 year experience from Australia. Vaccine 31, 691–697 (2013).
World Health Organization. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization. (World Health Organization, 2023).
U.S. Food & Drug Administration. Respiratory Syncytial Virus (RSV). https://www.fda.gov/consumers/covid-19-flu-and-rsv/respiratory-syncytial-virus-rsv (2024).
World Health Organization. A New Vaccine Will Change the Balance of the Fight Against Meningitis (World Health Organization, 2023).
Kenna, M. A. Acquired hearing loss in children. Otolaryngol. Clin. North Am. 48, 933–953 (2015).
Cohen, B. E., Durstenfeld, A. & Roehm, P. C. Viral causes of hearing loss: a review for hearing health professionals. Trends Hearing 18, 233121651454136 (2014).
Perny, M. et al. Streptococcus pneumoniae-induced ototoxicity in organ of Corti explant cultures. Hear. Res. 350, 100–109 (2017).
Douglas, S. A., Sanli, H. & Gibson, W. P. R. Meningitis resulting in hearing loss and labyrinthitis ossificans—does the causative organism matter? Cochlear Implants Int. 9, 90–96 (2008).
Sáez-Llorens, X. & McCracken, G. H. Bacterial meningitis in children. Lancet 361, 2139–2148 (2003).
Lucas, M. J., Brouwer, M. C. & van de Beek, D. Neurological sequelae of bacterial meningitis. J. Infect. 73, 18–27 (2016).
Du, Y., Wu, X. & Li, L. Mechanisms of bacterial meningitis-related deafness. Drug Discov. Today Dis. Mech. 3, 115–118 (2006).
Davis, L. E. Acute bacterial meningitis. Continuum 24, 1264–1283 (2018).
Kim, J., Vasan, S., Kim, J. H. & Ake, J. A. Current approaches to HIV vaccine development: a narrative review. J. Int. AIDS Soc. 24, e25793 (2021).
Pattnaik, A., Sahoo, B. R. & Pattnaik, A. K. Current status of Zika virus vaccines: successes and challenges. Vaccines 8, 266 (2020).
Poland, G. A., Ovsyannikova, I. G. & Kennedy, R. B. Zika vaccine development: current status. Mayo Clin. Proc. 94, 2572–2586 (2019).
Wang, Y., Ling, L., Zhang, Z. & Marin-Lopez, A. Current advances in Zika vaccine development. Vaccines 10, 1816 (2022).
Barbosa, M. H. D. M. et al. Auditory findings associated with Zika virus infection: an integrative review. Braz. J. Otorhinolaryngol. 85, 642–663 (2019).
Mitsikas, D., Gabrani, C., Giannakou, K. & Lamnisos, D. Intrauterine exposure to Zika virus and hearing loss within the first few years of life: a systematic literature review. Int. J. Pediatr. Otorhinolaryngol. 147, 110801 (2021).
Adler, S. P. et al. Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects. J. Infect. Dis. 220, 411–419 (2019).
World Health Organization. Malaria vaccine: WHO position paper—March 2022. https://www.who.int/publications/i/item/who-wer9709-61%E2%80%9380 (2022).
Zhao, S. Z. & Mackenzie, I. J. Deafness: malaria as a forgotten cause. Ann. Trop. Paediatr. 31, 1–10 (2011).
Tada, T. et al. A case of falciparum malaria: acute hearing loss as the initial symptom. J. Infect. Chemother. 23, 56–58 (2017).
Joshi, A., Gupta, N., Ish, P. & Chakrabarti, S. Cerebral malaria: hear before discharge! Indian J. Crit. Care Med 24, 212–213 (2020).
Mazur, N. I. et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect. Dis. 23, e2–e21 (2023).
Venkatesan, P. & First, R. S. V. vaccine approvals. Lancet Microbe 4, e577 (2023).
Rovers, M. M., Schilder, A. G. M., Zielhuis, G. A. & Rosenfeld, R. M. Otitis media. Lancet 363, 465–473 (2004).
Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV). https://www.cdc.gov/rsv/index.html (2020).
World Health Organization. World Report on Hearing (World Health Organization, 2021).
Kobayashi, M. et al. WHO consultation on group B Streptococcus vaccine development: report from a meeting held on 27–28 April 2016. Vaccine 37, 7307–7314 (2019).
Heath, P. T. et al. Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect. Dis. 17, e223–e234 (2017).
Salami, K., Gouglas, D., Schmaljohn, C., Saville, M. & Tornieporth, N. A review of Lassa fever vaccine candidates. Curr. Opin. Virol. 37, 105–111 (2019).
World Health Organization. Lassa fever. (2017).
Mateer, E. J., Huang, C., Shehu, N. Y. & Paessler, S. Lassa fever–induced sensorineural hearing loss: A neglected public health and social burden. PLOS Neglected Tropical Dis. 12, e0006187 (2018).
Ibekwe, T. S. et al. Early-onset sensorineural hearing loss in Lassa fever. Eur. Arch. Oto-Rhino-Laryngol. 268, 197–201 (2011).
Sharma, A. R., Lee, Y.-H., Nath, S. & Lee, S.-S. Recent developments and strategies of Ebola virus vaccines. Curr. Opin. Pharmacol. 60, 46–53 (2021).
World Health Organization. WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries. https://www.who.int/news/item/12-11-2019-who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries (2019).
Ficenec, S. C., Schieffelin, J. S. & Emmett, S. D. A review of hearing loss associated with Zika, Ebola, and Lassa fever. Am. J. Trop. Med. Hyg. 101, 484–490 (2019).
Clark, D. V. et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect. Dis. 15, 905–912 (2015).
World Health Organization. Ebola virus disease. (2021).
Westerberg, B. D., Atashband, S. & Kozak, F. K. A systematic review of the incidence of sensorineural hearing loss in neonates exposed to Herpes simplex virus (HSV). Int. J. Pediatr. Otorhinolaryngol. 72, 931–937 (2008).
Rabinstein, A., Jerry, J., Saraf–Lavi, E., Sklar, E. & Bradley, W. G. Sudden sensorineural hearing loss associated with herpes simplex virus type 1 infection. Neurology 56, 571 (2001).
Sohal, K., Moshy, J., Owibingire, S. & Shuaibu, I. Hearing loss in children: a review of literature. J. Med. Sci. 40, 149–161 (2020).
Johnston, C., Gottlieb, S. L. & Wald, A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine 34, 2948–2952 (2016).
Sandgren, K. J., Truong, N. R., Smith, J. B., Bertram, K. & Cunningham, A. L. Vaccines for herpes simplex: recent progress driven by viral and adjuvant immunology. Methods Mol. Biol. 2060, 31–56 (2020).
Piras, F., Plitnick, L. M., Berglund, P., Bernard, M. C. & Desert, P. Nonclinical safety evaluation of two vaccine candidates for herpes simplex virus type 2 to support combined administration in humans. J. Appl. Toxicol. 43, 534–556 (2023).
Chentoufi, A. A., et al. Combinatorial herpes simplex vaccine strategies: from bedside to bench and back. Front. Immunol. 13, 849515 (2022).
